外周血ERCC1-C8092 A基因型指导晚期食管癌个体化治疗的初步探讨

摘要

目的：初步探索外周血切除修复交叉互补基因1（ ERCC1）-C8092A位点多态性指导个体化治疗晚期食管癌患者的价值。方法120例晚期食管癌患者入组，随机选取40例为对照组予以顺铂联合紫杉醇方案化疗；80例干预组患者根据外周血ERCC1-C8092A位点基因型制定化疗方案，基因型为A／A或A／C型，采用顺铂联合紫杉醇方案化疗，基因型为C／C型，采用5-氟尿嘧啶联合紫杉醇方案化疗，每21天为1个周期，比较两组患者的近期有效率及不良反应的差异。结果对照组和干预组晚期食管癌患者近期有效率分别为31．6％和53．9％，差异有统计学意义（P＝0．024）；同样予以紫杉醇联合顺铂方案治疗下，对照组和干预组不良反应无统计学差异。结论根据外周血ERCC1-C8092A位点基因型制定化疗方案，可提高晚期食管癌患者的近期有效率，值得临床推广。%Objective To investigate the values of peripheral blood excision repair cross complementation group 1 ( ERCCI )-C8092A genetic polymorphisms in predicting the prognosis of advanced esophageal cancer patients on individual.Methods One hundred and twenty patients with advanced esophageal cancer were enrolled in this study.The control group 40 patients were received cisplatin and paclita-xel .80 patients in the intervention group,A/A or A/C were received cisplatin and paclitaxel;C/C were received 5-fluorouracil and paclitax-el,every 21ds for 1 cycle.Then the response rate( RR) and adverse reactions were analyzed.Results The control group and the intervention group of patients with advanced esophageal cancer response rates were 31.6% and 53.9% (P=0.024) .The adverse reactions were the same.Conclusion According to peripheral blood ERCC1-C8092A genotype choosing chemotherapy can improve the patients with advanced esophageal carcinoma response rate,which is worthy of further promotion.